Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00375830 · ClinicalTrials.gov registry record · Phase 2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

A Phase 2 study of Cancer, sponsored by Stanford University.

Completed
Registry status
Phase 2
Development phase
114
Enrollment target
1
Study location

NCT00375830: Completed Phase 2 study of Cancer, sponsored by Stanford University.

NCT00375830 is a Phase 2 study of Cancer that has completed, run by Stanford University. The registered enrollment target is 114 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00375830, a Phase 2 study of Cancer, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 2
Development phase
114 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Conditions Studied

Interventions

  • PROCEDURE Bone scan
  • DRUG 99mTc-methyl diphosphonate
  • PROCEDURE Positron Emission Tomography (PET) scan
  • DRUG 18F-Fludeoxyglucose (18F-FDG)
  • PROCEDURE Computed Tomography (CT) scan

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2006-01
Est. Completion 2019-03-14
Phase Phase 2

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT00375830

The ClinicalTrials.gov registry entry for NCT00375830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bone scan is the first listed.

NCT00375830 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00375830 about?

NCT00375830 is a clinical study titled "Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases". This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate canc...

What is the current status of trial NCT00375830?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2006-01. Estimated completion is 2019-03-14.

What conditions does trial NCT00375830 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT00375830?

The interventions under investigation include: Bone scan (PROCEDURE), 99mTc-methyl diphosphonate (DRUG), Positron Emission Tomography (PET) scan (PROCEDURE), 18F-Fludeoxyglucose (18F-FDG) (DRUG), Computed Tomography (CT) scan (PROCEDURE).

Who is sponsoring clinical trial NCT00375830?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00375830 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.